Literature DB >> 28786760

Association of OPRK1 gene polymorphisms with opioid dependence in addicted men undergoing methadone treatment in an Iranian population.

Ali Albonaim1, Hedyeh Fazel2, Alireza Sharafshah1, Vahid Omarmeli1, Sajjad Rezaei3, Farzam Ajamian4, Parvaneh Keshavarz5.   

Abstract

Previous studies have shown significant associations between OPRK1 and susceptibility to opioid dependence and the relationships between libido dysfunction and insomnia among opium addicts who underwent methadone maintenance treatment. The authors investigated the single locus and haplotype association of rs997917, rs6985606, and rs6473797 with susceptibility to opioid addiction. Samples were selected among 202 healthy individuals and 202 opium addicts undergoing methadone maintenance treatment. Genomic DNA was extracted from the whole blood samples of all subjects through a salting out procedure. All three variants were genotyped in the studied subjects using Amplification Refractory Mutation System-Polymerase Chain Reaction (ARMS-PCR). The whole analysis process was performed using SNPAlyze and SPSS ver.20 software packages. According to the single locus analyses, rs997917 and rs6985606 represented significant associations with opium addiction under recessive (p = 0.0128) and co-dominant (p = 0.0001) inheritance models, respectively. The haplotypes C-T-C (Permutation p = 0.014) and C-T-T (Permutation p = 0.0002) were significantly associated with opioid dependence. Among methadone maintenance treatment individuals, rs997917 was significantly associated with insomnia in both allelic and genotypic levels (p = 0.0001 and p = 0.038, respectively). Furthermore, rs6985606 had the only significant association with the co-incidence of insomnia and libido dysfunction in the methadone maintenance treatment group (p = 0.038). The OPRK1 gene variants showed significant association with susceptibility to opioid dependence among Iranians.

Entities:  

Keywords:  MMT; OPRK1; Variant; association; insomnia; libido dysfunction; opium addiction

Mesh:

Substances:

Year:  2017        PMID: 28786760     DOI: 10.1080/10550887.2017.1361724

Source DB:  PubMed          Journal:  J Addict Dis        ISSN: 1055-0887


  5 in total

Review 1.  Pharmacogenetics of Opioid Use Disorder Treatment.

Authors:  Richard C Crist; Toni-Kim Clarke; Wade H Berrettini
Journal:  CNS Drugs       Date:  2018-04       Impact factor: 5.749

2.  Kappa Opioid Signaling at the Crossroads of Chronic Pain and Opioid Addiction.

Authors:  Catherine M Cahill; Lindsay Lueptow; Hannah Kim; Raj Shusharla; Amy Bishop; Christopher J Evans
Journal:  Handb Exp Pharmacol       Date:  2022

Review 3.  A review of sleep disturbance in adults prescribed medications for opioid use disorder: potential treatment targets for a highly prevalent, chronic problem.

Authors:  Allison K Wilkerson; Aimee L McRae-Clark
Journal:  Sleep Med       Date:  2021-05-27       Impact factor: 4.842

Review 4.  Molecular Imaging of Opioid and Dopamine Systems: Insights Into the Pharmacogenetics of Opioid Use Disorders.

Authors:  Jamie A Burns; Danielle S Kroll; Dana E Feldman; Christopher Kure Liu; Peter Manza; Corinde E Wiers; Nora D Volkow; Gene-Jack Wang
Journal:  Front Psychiatry       Date:  2019-09-18       Impact factor: 4.157

Review 5.  Neuropharmacological and Neurogenetic Correlates of Opioid Use Disorder (OUD) As a Function of Ethnicity: Relevance to Precision Addiction Medicine.

Authors:  Tomilowo Abijo; Kenneth Blum; Marjorie C Gondré-Lewis
Journal:  Curr Neuropharmacol       Date:  2020       Impact factor: 7.363

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.